PSYCHIATRIC ISSUES tied to the use of oral sildenafil (Viagra) for erectile dysfunction (ED)
provokedstronginterest at the annual meeting of the American Psychiatric Association (APA)
in Toronto, Ontario, in June. Psychiatrists' craving for information, however, went unrequited.
There were no formal presentations on ED, perhaps because Viagra had been approved for
sale in the United States only in March. In the meeting's commercial exhibit area,
representatives of the drug's manufacturer, Pfizer Inc, New York, NY, claimed they could not …